SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AZN: AstraZeneca PLC
AZN 82.44-0.2%2:17 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eugene E. Dorsey who wrote (29)5/21/2006 9:12:01 AM
From: Eugene E. Dorsey  Read Replies (1) of 35
 
Reasons for AVNR@$56.00
Milestones for Development of Novel Therapeutics for Inflammation
w/Novartis ..................................................................... April 2005

Over 200 million in milestone payments.
Progress ..................................................... Milestones Payments
Any day now phase I ............................................. $
?????????????? phase II ............................................ $$
????????????? phase III .............................................. $$$
FDA approval ......................................................... $$$$

Milestones for Novel Reverse Cholesterol Transport Enhancing Compounds
w/AstraZeneca PLC ......................................................... July 2005

Upfront 10 million w/milestones up to 330 million
Progress ................................................... Milestones Payments
Jan 2006 phase 1 ................................................ rec'd 5 million milestone
?????????????? phase II ............................................ $$
?????????????? phase III ............................................ $$$
FDA approval......................................................... $$$$

One Self funded phase III trial
Diabetic Neuropathic Pain.................................. began June 2005

Completed NDA for involuntary emotional expression disorder, also known as pseudobulbar affect or emotional lability..... Jan 2006
(a) Avanir's Neurodex NDA accepted with priority review for Involuntary Emotional Expression Disorder..... April 2006
(b) Avanir completed the submission of its NDA to the FDA on January 27, 2006 and expects the FDA will take action on the NDA by July 30, 2006 (the "PDUFA date").
biz.yahoo.com

The Company's first commercialized product, abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about Avanir can be found at avanir.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News